Physician profile
Jay A Johnson
NPI 1699810697
$6,059.15
in general payments reported to CMS, 2019-2025
26 companies · $830 in 2025
The $830 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,499 · 2020: $558 · 2021: $956 · 2022: $426 · 2023: $1,531 · 2024: $258 · 2025: $830.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,911 · Travel and Lodging: $709.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,910.62 |
| Travel and Lodging | $708.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,106.75 | 2021-2025 | Azure Xt Dr Mri Surescan, Linq II, Micra |
| Abbott Laboratories | $720.99 | 2019-2025 | Gallant, Amplatzer Talisman, Assurity |
| Medtronic Vascular, INC. | $551.56 | 2019-2020 | |
| Amgen INC. | $546.87 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $263.47 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.93 | 2019-2022 | |
| Boston Scientific Corporation | $228.44 | 2019-2024 | Lux-Dx Insertable Cardiac Monitor, Dynagen Mini Icd Vr, Accolade Sr |
| E.R. Squibb & Sons, L.L.C. | $223.51 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $209.88 | 2019-2022 | |
| Pfizer INC. | $187.72 | 2019-2025 | |
| Heartflow, INC. | $169.17 | 2025 | |
| Sanofi-Aventis U.S. LLC | $124.58 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $114.24 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $79.48 | 2019 | |
| Glaxosmithkline, LLC. | $40.59 | 2025 | Shingrix, Arexvy |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $37.49 | 2025 | Fibryga |
| Bridgebio Pharma, INC. | $33.78 | 2025 | Attruby |
| Kiniksa Pharmaceuticals, Ltd. | $31.39 | 2021 | |
| Edwards Lifesciences Corporation | $31.05 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Amarin Pharma, INC. | $24.30 | 2022 | |
| Novo Nordisk INC | $21.05 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $19.83 | 2022 | |
| Lundbeck LLC | $17.73 | 2020 | |
| Biogen, INC. | $17.60 | 2025 | Tysabri, Vumerity |
| Biotronik INC. | $16.50 | 2023 | |
| Shockwave Medical, INC | $11.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.